As the Mental Health Pandemic spirals out of control, we see a positive sign: the mainstream media has finally noticed it.
As the Mental Health Pandemic spirals out of control, we see a positive sign: the mainstream media has finally noticed it.
MindMed officially announces its inclusion in the FTSE Russell 3000.
Cybin Inc releases its full-year financial results for the fiscal year ended March 31, 2021 and provides business highlights.
Psyched Wellness announces its latest pre-clinical study on AME-1.
In pre-clinical testing, multiple proprietary molecules "showed consistent positive results when compared to the parent molecule".
Compass Pathways completes the world's largest psilocybin-based clinical trial as the 216th patient in its trial completed their treatment.
Field Trip reports Q4 and full-year results for fiscal 2021. Cash position of CAD$111m. Clinic revenues increased by 63% q-o-q to CAD$526,435.
Psychedelic Stock Watch explains why astute investors will put their dollars into both "experiential" and non-psychoactive psychedelic drug R&D.
The newest member of Cybin's Clinical Advisory Board previously held a senior position with the FDA.
Mydecine's novel molecule, MYCO-004 is targeting multiple forms of addiction/substance abuse.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now